ArticleAnalytical and bioanalytical chemistry2026
DNA nanocage-assisted multiplex fluorescence quantification of size-fractionated low-mass soluble amyloid-β oligomers.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Low-mass soluble amyloid-β oligomers (LSAβOs) are increasingly recognized as key neurotoxic species in Alzheimer's disease, yet their structural heterogeneity and low abundance hinder fraction-specific quantitative analysis. Herein, we report a DNA nanocage-assisted multiplex fluorescence analytical platform for size-fractionated detection of LSAβOs in cerebrospinal fluid (CSF). The platform integrates size-selective nanocage recognition with a coupled catalytic hairpin assembly (CHA)-DNAzyme signal amplification architecture. Three customizable DNA nanocages with distinct cavity dimensions act as molecular size sieves, enabling differential capture of LSAβO fractions enriched in <10 kD, 10-30 kD, and 30-50 kD species. The released trigger strands initiate CHA-DNAzyme amplification, generating fluorescence signals that are subsequently resolved via signal deconvolution to yield apparent fraction-specific concentrations. The method achieves detection limits of 5 and 10 pM (S/N = 3) and demonstrates satisfactory recovery in spiked diluted CSF samples. This work establishes an analytical strategy that advances DNA nanocage-based sensing from size-selective recognition toward multiplex amplified quantitative profiling of heterogeneous amyloid oligomers.
Indexed as
Identifiers
42213122What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.